Income Statement Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 12:00:00 15/05/2026 pm IST			5-day change	1st Jan Change
2,574.00 ^JPY	-0.31%		-1.00%	-23.12%

03:50am	FDA approves Daiichi Sankyo's fam-trastuzumab deruxtecan-nxki for two breast cancer indications	RE
16/05	Breast Cancer Treatment from Daiichi Sankyo, AstraZeneca Approved in U.S.	DJ

fe8d585438da.q-EXoERjKcEZhFf8sOR6IWn8jaSSwoQHAp1rxacg6R0._pJvzR1aBI9hsjG2840Tdw6Zx9T2qe5wacQkqeJv3nD8hlbiPS9Og07PIA

Published financial data: DAIICHI SANKYO COMPANY, LIMITED

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2021	2022	2023	2024	2025
Revenues	96TCr	1,04500Cr	1,27800Cr	1,60200Cr	1,88600Cr
Total Revenues	96TCr	1,04500Cr	1,27800Cr	1,60200Cr	1,88600Cr
Cost of Goods Sold, Total	34TCr	35TCr	36TCr	42TCr	42TCr
Gross Profit	62TCr	69TCr	91TCr	1,18600Cr	1,47000Cr
Selling General & Admin Expenses, Total	33TCr	36TCr	47TCr	64TCr	73TCr
R&D Expenses	23TCr	26TCr	34TCr	37TCr	44TCr
Other Operating Expenses	-	-	23Cr	-2.73TCr	-863Cr
Other Operating Expenses, Total	56TCr	62TCr	81TCr	97TCr	1,15900Cr
Operating Income	6.38TCr	7.3TCr	10TCr	21TCr	31TCr
Interest Expense, Total	-183.9Cr	-194.1Cr	-212Cr	-203.7Cr	-212.8Cr
Interest And Investment Income	270.9Cr	286.3Cr	972.8Cr	2.29TCr	2.68TCr
Net Interest Expenses	87Cr	92Cr	760.8Cr	2.09TCr	2.47TCr
Income (Loss) On Equity Invest.	17Cr	13Cr	-1.9Cr	18Cr	145.7Cr
Currency Exchange Gains (Loss)	90Cr	-22Cr	62Cr	43Cr	-403.4Cr
Other Non Operating Income (Expenses)	911.6Cr	170.9Cr	377.8Cr	508Cr	603.8Cr
EBT, Excl. Unusual Items	7.49TCr	7.56TCr	11TCr	24TCr	34TCr
Gain (Loss) On Sale Of Investments	-	-	590.7Cr	88Cr	1.63TCr
Gain (Loss) On Sale Of Assets	-	-	1.27TCr	11Cr	372.6Cr
Asset Writedown	-73Cr	-205.3Cr	-571.3Cr	-183.1Cr	-440.2Cr
EBT, Incl. Unusual Items	7.41TCr	7.35TCr	13TCr	24TCr	36TCr
Income Tax Expense	-170.6Cr	654.3Cr	1.77TCr	3.62TCr	5.99TCr
Earnings From Continuing Operations	7.58TCr	6.7TCr	11TCr	20TCr	30TCr
Net Income to Company	7.58TCr	6.7TCr	11TCr	20TCr	30TCr
Minority Interest	13Cr	-	-	-28Cr	-
Net Income - (IS)	7.6TCr	6.7TCr	11TCr	20TCr	30TCr
Net Income to Common Incl Extra Items	7.6TCr	6.7TCr	11TCr	20TCr	30TCr
Net Income to Common Excl. Extra Items	7.6TCr	6.7TCr	11TCr	20TCr	30TCr
Per Share Items
Net EPS - Basic	39.17	34.94	56.96	104.69	155.96
Basic EPS - Continuing Operations	39.17	34.94	56.96	104.69	155.96
Basic Weighted Average Shares Outstanding	193.93Cr	191.66Cr	191.7Cr	191.74Cr	189.64Cr
Net EPS - Diluted	39.11	34.91	56.91	104.62	155.87
Diluted EPS - Continuing Operations	39.11	34.91	56.91	104.62	155.87
Diluted Weighted Average Shares Outstanding	194.2Cr	191.85Cr	191.86Cr	191.87Cr	189.75Cr
Normalized Basic EPS	24.19	24.64	37.14	77.46	112.07
Normalized Diluted EPS	24.16	24.62	37.11	77.41	112
Dividend Per Share	27	27	30	50	60
Payout Ratio	64.44	77.24	50.02	33.42	38.65
American Depositary Receipts Ratio (ADR)	1	1	1	1	1
Supplemental Items
EBITDA	12TCr	13TCr	17TCr	27TCr	38TCr
EBITA	6.38TCr	7.3TCr	10TCr	21TCr	31TCr
EBIT	6.38TCr	7.3TCr	10TCr	21TCr	31TCr
Effective Tax Rate - (Ratio)	-2.3	8.9	13.93	15.27	16.84
Normalized Net Income	4.69TCr	4.72TCr	7.12TCr	15TCr	21TCr
Non-Cash Pension Expense	1.65TCr	1.82TCr	2.15TCr	2.59TCr	3.15TCr
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	23TCr	26TCr	34TCr	37TCr	44TCr

Fiscal Period: March	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	38TCr	66TCr	44TCr	65TCr	64TCr
Total Cash And Short Term Investments	38TCr	66TCr	44TCr	65TCr	64TCr
Accounts Receivable, Total	23TCr	27TCr	35TCr	45TCr	62TCr
Total Receivables	23TCr	27TCr	35TCr	45TCr	62TCr
Inventory	20TCr	22TCr	30TCr	44TCr	51TCr
Other Current Assets, Total	45TCr	20TCr	40TCr	63TCr	14TCr
Total Current Assets	1,26800Cr	1,34500Cr	1,49500Cr	2,17400Cr	1,90900Cr
Net Property Plant And Equipment	27TCr	30TCr	35TCr	42TCr	50TCr
Long-term Investments	17TCr	19TCr	23TCr	34TCr	40TCr
Goodwill	7.77TCr	8.36TCr	9.83TCr	11TCr	24TCr
Other Intangibles, Total	17TCr	16TCr	16TCr	17TCr	10TCr
Deferred Tax Assets Long-Term	13TCr	14TCr	18TCr	25TCr	31TCr
Other Long-Term Assets, Total	30L	20L	40L	40L	30L
Total Assets	2,08500Cr	2,22100Cr	2,50900Cr	3,46100Cr	3,45600Cr
Liabilities
Accounts Payable, Total	30TCr	32TCr	42TCr	56TCr	58TCr
Short-term Borrowings	39Cr	39Cr	2.04TCr	40Cr	40Cr
Current Portion of Long-Term Debt	2TCr	2TCr	2.1TCr	-	-
Current Portion of Leases	928.7Cr	1.07TCr	1.09TCr	1.24TCr	1.47TCr
Current Income Taxes Payable	609.6Cr	691Cr	2.15TCr	4.64TCr	6.04TCr
Other Current Liabilities	2.03TCr	3.25TCr	3.24TCr	9.56TCr	9.86TCr
Total Current Liabilities	35TCr	40TCr	53TCr	71TCr	75TCr
Long-Term Debt	16TCr	14TCr	10TCr	10TCr	10TCr
Long-Term Leases	3.31TCr	3.95TCr	3.88TCr	4.18TCr	3.98TCr
Pension & Other Post Retirement Benefits	392.9Cr	262.4Cr	131Cr	129.1Cr	155.9Cr
Deferred Tax Liability Non Current	1.75TCr	1.24TCr	1.26TCr	1.29TCr	1.11TCr
Other Non Current Liabilities	24TCr	28TCr	38TCr	90TCr	93TCr
Total Liabilities	81TCr	87TCr	1,06300Cr	1,77300Cr	1,83300Cr
Common Stock, Total	5TCr	5TCr	5TCr	5TCr	5TCr
Additional Paid In Capital	9.45TCr	-	-	196.2Cr	-
Retained Earnings	1,27700Cr	1,17000Cr	1,23200Cr	1,38900Cr	1,45700Cr
Treasury Stock	-26TCr	-3.75TCr	-3.68TCr	-3.66TCr	-15TCr
Comprehensive Income and Other	11TCr	17TCr	20TCr	28TCr	26TCr
Total Common Equity	1,27200Cr	1,35100Cr	1,44600Cr	1,68800Cr	1,62300Cr
Minority Interest	-	-	-	43Cr	-
Total Equity	1,27200Cr	1,35100Cr	1,44600Cr	1,68900Cr	1,62300Cr
Total Liabilities And Equity	2,08500Cr	2,22100Cr	2,50900Cr	3,46100Cr	3,45600Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	191.64Cr	191.68Cr	191.73Cr	191.75Cr	186.26Cr
ECS Total Common Shares Outstanding	191.62Cr	191.68Cr	191.73Cr	191.75Cr	186.67Cr
Book Value / Share	663.85	704.76	754.09	880.4	869.69
Tangible Book Value	1,02200Cr	1,10300Cr	1,18800Cr	1,41100Cr	1,27900Cr
Tangible Book Value Per Share	533.11	575.67	619.56	736.05	685.26
Total Debt	23TCr	21TCr	19TCr	16TCr	16TCr
Net Debt	-15TCr	-45TCr	-25TCr	-49TCr	-48TCr
Debt Equivalent of Unfunded Proj. Benefit Obligation	-2.37TCr	-3.28TCr	-4.37TCr	-6.71TCr	-7.11TCr
Minority Interest, Total (Incl. Fin. Div)	-	-	-	43Cr	-
Equity Method Investments, Total	144Cr	142.5Cr	130.6Cr	61Cr	560Cr
Inventories - Raw Materials, Total	3.66TCr	4.98TCr	10TCr	19TCr	25TCr
Inventories - Work In Process, Total	1.91TCr	1.87TCr	2.92TCr	2.46TCr	3.3TCr
Inventories - Finished Goods, Total	15TCr	15TCr	17TCr	22TCr	23TCr
Inventories - Others	10L	10L	10L	10L	20L
Full Time Employees	16.03T	16.46T	17.44T	18.73T	19.76T
Accumulated Allowance for Doubtful Accounts (Supple)	64Cr	92Cr	68Cr	96Cr	67Cr

Fiscal Period: March	2021	2022	2023	2024	2025
Net Income	7.41TCr	7.35TCr	13TCr	24TCr	36TCr
Depreciation & Amortization - CF	5.74TCr	5.82TCr	6.78TCr	5.96TCr	6.86TCr
Depreciation & Amortization, Total	5.74TCr	5.82TCr	6.78TCr	5.96TCr	6.86TCr
(Gain) Loss From Sale Of Asset	143.6Cr	774.6Cr	785.5Cr	212.4Cr	181.8Cr
(Income) Loss On Equity Investments - (CF)	-17Cr	-13Cr	1.9Cr	-18Cr	-145.7Cr
Other Operating Activities, Total	-3.36TCr	-2.19TCr	-4.69TCr	-11TCr	-11TCr
Change In Accounts Receivable	8.31TCr	-1.91TCr	-6.46TCr	-6.99TCr	-17TCr
Change In Inventories	-2.12TCr	-60Cr	-8.07TCr	-13TCr	-7.84TCr
Change In Accounts Payable	2.39TCr	1.33TCr	5.41TCr	12TCr	4.01TCr
Change in Other Net Operating Assets	731.5Cr	2.81TCr	5.01TCr	48TCr	-5.56TCr
Cash from Operations	19TCr	14TCr	11TCr	60TCr	5.38TCr
Capital Expenditure	-3.12TCr	-6.27TCr	-6.07TCr	-8.83TCr	-12TCr
Sale of Property, Plant, and Equipment	3.3Cr	526Cr	994.1Cr	52Cr	50Cr
Cash Acquisitions	-440.1Cr	-	-3.08TCr	-690Cr	-
Divestitures	-	-	830.2Cr	750Cr	525Cr
Sale (Purchase) of Intangible assets	-3.28TCr	-1.39TCr	-661.7Cr	-3.45TCr	-7.16TCr
Investment in Marketable and Equity Securities, Total	2.9TCr	28TCr	-19TCr	-16TCr	52TCr
Net (Increase) Decrease in Loans Originated / Sold - Investing	70Cr	38Cr	31Cr	17Cr	1.8Cr
Other Investing Activities, Total	-45Cr	3.9Cr	810.1Cr	381.9Cr	50Cr
Cash from Investing	-3.92TCr	21TCr	-26TCr	-28TCr	33TCr
Long-Term Debt Issued, Total	-	-	-	48Cr	-
Total Debt Issued	-	-	-	48Cr	-
Long-Term Debt Repaid, Total	-4.04TCr	-2.04TCr	-2.04TCr	-4.14TCr	-40Cr
Total Debt Repaid	-4.04TCr	-2.04TCr	-2.04TCr	-4.14TCr	-40Cr
Issuance of Common Stock	20L	-	-	-	-
Repurchase of Common Stock	-10TCr	-1.5Cr	-2.4Cr	-2.5Cr	-25TCr
Common Dividends Paid	-4.89TCr	-5.17TCr	-5.46TCr	-6.71TCr	-11TCr
Common & Preferred Stock Dividends Paid	-4.89TCr	-5.17TCr	-5.46TCr	-6.71TCr	-11TCr
Other Financing Activities, Total	-1.29TCr	-1.41TCr	-1.46TCr	-1.55TCr	-1.7TCr
Cash from Financing	-20TCr	-8.62TCr	-8.96TCr	-12TCr	-38TCr
Foreign Exchange Rate Adjustments	583.4Cr	1.66TCr	1.23TCr	2.14TCr	-1.76TCr
Miscellaneous Cash Flow Adjustments	10L	-	-	-922.3Cr	-10L
Net Change in Cash	-4.36TCr	28TCr	-22TCr	21TCr	-734.2Cr
Supplemental Items
Cash Interest Paid	183.9Cr	177.9Cr	208Cr	184.4Cr	192.9Cr
Cash Income Tax Paid (Refund)	2.45TCr	2.26TCr	4.62TCr	9.68TCr	11TCr
Levered Free Cash Flow	13TCr	27TCr	-19TCr	-18TCr	37TCr
Unlevered Free Cash Flow	13TCr	27TCr	-19TCr	-18TCr	37TCr
Change In Net Working Capital	-9.48TCr	-25TCr	26TCr	25TCr	-30TCr
Net Debt Issued / Repaid	-4.04TCr	-2.04TCr	-2.04TCr	-4.09TCr	-40Cr

Fiscal Period: March	2021	2022	2023	2024	2025
Profitability
Return on Assets	1.9	2.12	2.69	4.43	5.64
Return on Total Capital	2.6	2.98	3.98	7.59	10.76
Return On Equity %	5.88	5.11	7.81	12.83	17.86
Return on Common Equity	5.89	5.11	7.81	12.81	17.86
Margin Analysis
Gross Profit Margin %	64.85	66.19	71.57	74.07	77.96
SG&A Margin	34.6	34.29	36.86	39.77	38.76
EBITDA Margin %	12.59	12.56	13.27	16.93	20.18
EBITA Margin %	6.63	6.99	7.97	13.2	16.54
EBIT Margin %	6.63	6.99	7.97	13.2	16.54
Income From Continuing Operations Margin %	7.88	6.41	8.54	12.55	15.68
Net Income Margin %	7.89	6.41	8.54	12.53	15.68
Net Avail. For Common Margin %	7.89	6.41	8.54	12.53	15.68
Normalized Net Income Margin	4.87	4.52	5.57	9.27	11.27
Levered Free Cash Flow Margin	13.17	25.97	-15.16	-11.54	19.69
Unlevered Free Cash Flow Margin	13.29	26.09	-15.05	-11.46	19.77
Asset Turnover
Asset Turnover	0.46	0.49	0.54	0.54	0.55
Fixed Assets Turnover	3.76	3.67	3.92	4.16	4.1
Receivables Turnover (Average Receivables)	3.56	4.19	4.15	3.99	3.51
Inventory Turnover (Average Inventory)	1.81	1.69	1.4	1.12	0.87
Short Term Liquidity
Current Ratio	3.59	3.4	2.82	3.05	2.53
Quick Ratio	1.73	2.35	1.49	1.55	1.67
Operating Cash Flow to Current Liabilities	0.54	0.35	0.22	0.84	0.07
Days Sales Outstanding (Average Receivables)	102.65	87.1	87.9	91.78	103.84
Days Outstanding Inventory (Average Inventory)	201.88	216.3	260.81	325.94	418.3
Average Days Payable Outstanding	283.57	306.62	305.57	325.38	421.28
Cash Conversion Cycle (Average Days)	20.97	-3.22	43.14	92.34	100.86
Long Term Solvency
Total Debt/Equity	17.78	15.81	13.34	9.24	9.6
Total Debt / Total Capital	15.1	13.65	11.77	8.46	8.76
LT Debt/Equity	15.45	13.51	9.72	8.48	8.67
Long-Term Debt / Total Capital	13.12	11.67	8.58	7.76	7.91
Total Liabilities / Total Assets	39	39.19	42.37	51.21	53.03
EBIT / Interest Expense	34.69	37.62	48.08	103.82	146.58
EBITDA / Interest Expense	65.89	67.63	80.06	133.1	178.84
(EBITDA - Capex) / Interest Expense	48.9	35.31	51.4	89.74	124.21
Total Debt / EBITDA	1.87	1.63	1.14	0.58	0.41
Net Debt / EBITDA	-1.27	-3.42	-1.47	-1.81	-1.27
Total Debt / (EBITDA - Capex)	2.51	3.12	1.77	0.85	0.59
Net Debt / (EBITDA - Capex)	-1.72	-6.55	-2.29	-2.69	-1.83
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-1.96	8.56	22.36	25.28	17.77
Gross Profit, 1 Yr. Growth %	-2.25	10.79	32.3	29.66	23.95
EBITDA, 1 Yr. Growth %	-36.69	8.33	29.29	59.75	40.37
EBITA, 1 Yr. Growth %	-54.04	14.47	39.58	107.48	47.49
EBIT, 1 Yr. Growth %	-54.04	14.47	39.58	107.48	47.49
Earnings From Cont. Operations, 1 Yr. Growth %	-41.2	-11.68	63.04	84.1	47.13
Net Income, 1 Yr. Growth %	-41.15	-11.83	63.04	83.84	47.34
Normalized Net Income, 1 Yr. Growth %	-47.78	0.68	50.74	108.6	43.1
Diluted EPS Before Extra, 1 Yr. Growth %	-40.98	-10.74	63.02	83.83	48.99
Accounts Receivable, 1 Yr. Growth %	-25	14.93	30.91	30.1	36.31
Inventory, 1 Yr. Growth %	15.86	8.49	38.41	45.26	17.53
Net Property, Plant and Equip., 1 Yr. Growth %	7.38	14.62	14.75	20.86	18.22
Total Assets, 1 Yr. Growth %	-0.97	6.53	12.94	37.95	-0.14
Tangible Book Value, 1 Yr. Growth %	-3.32	8.02	7.66	18.81	-9.37
Common Equity, 1 Yr. Growth %	-2.59	6.2	7.03	16.76	-3.84
Cash From Operations, 1 Yr. Growth %	-2.24	-27.56	-17.75	423.31	-91.02
Capital Expenditures, 1 Yr. Growth %	-2.16	100.79	-3.17	45.39	31.63
Levered Free Cash Flow, 1 Yr. Growth %	-45.56	114.05	-171.41	-4.62	-301
Unlevered Free Cash Flow, 1 Yr. Growth %	-45.4	113.07	-170.61	-4.63	-303.12
Dividend Per Share, 1 Yr. Growth %	15.71	0	11.11	66.67	20
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	1.75	3.16	15.25	23.81	21.47
Gross Profit, 2 Yr. CAGR %	5.1	4.07	21.07	30.98	26.77
EBITDA, 2 Yr. CAGR %	-3.41	-17.19	18.35	43.71	49.75
EBITA, 2 Yr. CAGR %	-12.7	-27.47	26.4	70.18	74.94
EBIT, 2 Yr. CAGR %	-12.7	-27.47	26.4	70.18	74.94
Earnings From Cont. Operations, 2 Yr. CAGR %	-9.9	-27.94	20	73.25	64.58
Net Income, 2 Yr. CAGR %	-9.82	-27.97	19.89	73.13	64.58
Normalized Net Income, 2 Yr. CAGR %	-7.36	-27.49	23.19	77.33	72.78
Diluted EPS Before Extra, 2 Yr. CAGR %	-9.7	-27.42	20.63	73.11	65.5
Accounts Receivable, 2 Yr. CAGR %	-25.64	-7.16	22.66	30.5	33.17
Inventory, 2 Yr. CAGR %	6.81	12.11	22.54	41.79	30.66
Net Property, Plant and Equip., 2 Yr. CAGR %	7.61	10.94	14.68	17.76	19.53
Total Assets, 2 Yr. CAGR %	-0.07	2.71	9.69	24.82	17.37
Tangible Book Value, 2 Yr. CAGR %	0.95	2.19	7.84	13.1	3.77
Common Equity, 2 Yr. CAGR %	0.89	1.71	6.61	11.79	5.96
Cash From Operations, 2 Yr. CAGR %	44.51	-15.85	-22.81	107.47	-31.43
Capital Expenditures, 2 Yr. CAGR %	-6.98	40.16	39.44	18.65	38.34
Levered Free Cash Flow, 2 Yr. CAGR %	-30.78	7.95	23.63	-17.47	38.46
Unlevered Free Cash Flow, 2 Yr. CAGR %	-30.27	7.86	22.65	-17.94	39.18
Dividend Per Share, 2 Yr. CAGR %	7.57	7.57	5.41	36.08	41.42
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	0.08	3.97	9.2	18.5	21.76
Gross Profit, 3 Yr. CAGR %	0.54	6.96	12.74	23.87	28.59
EBITDA, 3 Yr. CAGR %	-0.49	0.36	-3.93	30.79	42.59
EBITA, 3 Yr. CAGR %	-5.79	-4.45	-9.78	49.11	62.25
EBIT, 3 Yr. CAGR %	-5.79	-4.45	-9.78	49.11	62.25
Earnings From Cont. Operations, 3 Yr. CAGR %	8.23	-10.5	-5.4	38.4	64.06
Net Income, 3 Yr. CAGR %	8.01	-10.5	-5.42	38.25	64.06
Normalized Net Income, 3 Yr. CAGR %	-3.29	-4.76	-7.46	46.84	65.09
Diluted EPS Before Extra, 3 Yr. CAGR %	8.8	-10.05	-4.95	38.82	64.67
Accounts Receivable, 3 Yr. CAGR %	0.07	-14.02	4.11	25.09	32.41
Inventory, 3 Yr. CAGR %	5.19	7.37	20.27	29.69	33.19
Net Property, Plant and Equip., 3 Yr. CAGR %	6.77	9.9	12.2	16.71	17.91
Total Assets, 3 Yr. CAGR %	3.19	2.08	6.01	18.4	15.87
Tangible Book Value, 3 Yr. CAGR %	4.94	3.26	3.98	11.38	5.05
Common Equity, 3 Yr. CAGR %	3.93	2.63	3.45	9.89	6.32
Cash From Operations, 3 Yr. CAGR %	21.02	14.8	-16.49	46.09	-27.14
Capital Expenditures, 3 Yr. CAGR %	10.12	20.22	23.9	41.39	22.83
Levered Free Cash Flow, 3 Yr. CAGR %	-9.3	0.85	-5.94	13.39	11.04
Unlevered Free Cash Flow, 3 Yr. CAGR %	-9.33	1.18	-6.35	12.79	11
Dividend Per Share, 3 Yr. CAGR %	4.99	4.99	8.74	22.8	30.5
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-0.49	1.81	5.89	11.49	13.95
Gross Profit, 5 Yr. CAGR %	-1.34	2.69	8.3	15.99	18.15
EBITDA, 5 Yr. CAGR %	-7.06	-0.75	6.66	15.86	14.73
EBITA, 5 Yr. CAGR %	-13.33	-3.86	5.97	20.37	17.58
EBIT, 5 Yr. CAGR %	-13.33	-3.86	5.97	20.37	17.58
Earnings From Cont. Operations, 5 Yr. CAGR %	-1.16	7.12	12.79	16.56	18.06
Net Income, 5 Yr. CAGR %	-1.59	4.61	12.62	16.53	18.04
Normalized Net Income, 5 Yr. CAGR %	-9.99	-5.07	6.54	22.13	18.79
Diluted EPS Before Extra, 5 Yr. CAGR %	-0.3	5.68	13.39	16.88	18.66
Accounts Receivable, 5 Yr. CAGR %	-1.38	2.84	8.56	1.6	14.88
Inventory, 5 Yr. CAGR %	6.84	7.31	11.81	20	24.32
Net Property, Plant and Equip., 5 Yr. CAGR %	1.18	6.9	9.87	12.98	15.07
Total Assets, 5 Yr. CAGR %	1.87	3.01	5.74	10.64	10.42
Tangible Book Value, 5 Yr. CAGR %	1.63	4.62	6.09	7.08	3.9
Common Equity, 5 Yr. CAGR %	0.65	2.81	5	6.2	4.45
Cash From Operations, 5 Yr. CAGR %	1.98	0.44	1.1	45.46	-22.82
Capital Expenditures, 5 Yr. CAGR %	2.86	20.43	21.02	19.59	29.49
Levered Free Cash Flow, 5 Yr. CAGR %	-5.55	51.7	2.66	-6.92	9.79
Unlevered Free Cash Flow, 5 Yr. CAGR %	-5.28	53.18	2.32	-6.95	9.73
Dividend Per Share, 5 Yr. CAGR %	6.19	2.96	5.15	16.47	20.79